Please assess the completion status of the following clinical trial:

Trial Title: Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-70 years~* type 2 diabetes mellitus~* with or without hypertension~Exclusion Criteria:~* ischemic changes on resting electrocardiogram,~* clinical evidence of heart disease (angina, heart failure, unstable angina),cerebrovascular or peripheral vascular disease,~* significant cardiac arrhythmias,~* aortic stenosis,~* 2nd or 3rd degree atrio-ventricular block, sinus node disease, or symptomatic bradycardia,~* bronchospastic lung disease with active wheezing,~* known hypersensitivity to adenosine,~* hemoglobin A1C (HbA1c) \> 8.5%, \*~* gout (If not already taking HCTZ),~* the use of Rosiglitazone,\*\*~* estimated glomerular filtration rate (eGFR) \< 60 ml/min,~* serum potassium \> 5.0 mmol/L,~* use of potassium-sparing diuretics,\*\*~* current smoker,\*~* pregnancy,~* renal disease not related to diabetes mellitus,~* uncontrolled hypertension, systolic blood pressure (BP) \>160 mm Hg and diastolic BP \>100 mm Hg,\*~* use of cyclic hormone replacement therapy~* past intolerance of angiotensin-converting enzyme (ACE) inhibitor therapy~* other major medical illnesses. Participants with evidence of a previous myocardial infarction on the first adenosine-stimulated positron emission tomography (PET) study will be withdrawn from the study.~* Screening systolic blood pressure \< 105 mm Hg off of anti-hypertensive medications~  * Participants can enroll in study and proceed with in-patient evaluations if during the run-in period adjustments of medications, diet and habits lead to improved glucose control \[equivalent to HbA1c \<8.5%, controlled hypertension and cessation of smoking.~    * Participants who are currently taking these medications will not qualify for a screening visit. If medications were recently stopped by the participant's physician, he or she may be screened but the baseline assessment protocol must occur 3 months after stopping.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (mineralocorticoid receptor [MR] blockade) (Type: EXPERIMENTAL): None
- Hydrochlorothiazide + potassium (Type: ACTIVE_COMPARATOR): None
- Placebo capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).